Valmark Advisers Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,109 shares of the company's stock after purchasing an additional 234 shares during the period. Valmark Advisers Inc.'s holdings in Johnson & Johnson were worth $3,775,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Morton Brown Family Wealth LLC increased its holdings in Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company's stock worth $32,000 after acquiring an additional 78 shares during the period. Goodman Advisory Group LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $39,000. First Bank & Trust grew its stake in Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company's stock worth $67,000 after buying an additional 156 shares in the last quarter. Heritage Wealth Management LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $84,000. Finally, Timber Creek Capital Management LLC grew its stake in Johnson & Johnson by 225.0% in the 3rd quarter. Timber Creek Capital Management LLC now owns 650 shares of the company's stock worth $106,000 after buying an additional 450 shares in the last quarter. Institutional investors own 67.94% of the company's stock.
Get Johnson & Johnson alerts:Wall Street Analysts Forecast Growth
JNJ has been the subject of a number of research reports. Barclays initiated coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They issued an "equal weight" rating and a $175.00 price target for the company. StockNews.com started coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a "strong-buy" rating on the stock. SVB Leerink decreased their target price on Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a research report on Friday, January 20th. Atlantic Securities boosted their target price on Johnson & Johnson from $160.00 to $168.00 and gave the stock a "neutral" rating in a research report on Wednesday. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $176.00 to $180.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $182.75.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the company's stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, VP Thibaut Mongon sold 35,246 shares of the company's stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares of the company's stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Ashley Mcevoy sold 73,323 shares of the company's stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares of the company's stock, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock worth $40,960,735 over the last three months. 0.35% of the stock is owned by insiders.Johnson & Johnson Stock Down 0.4 %
Shares of NYSE:JNJ opened at $168.89 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The stock's fifty day simple moving average is $175.90 and its 200-day simple moving average is $171.04. The company has a market capitalization of $441.56 billion, a P/E ratio of 25.06, a P/E/G ratio of 3.00 and a beta of 0.56.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.22 by $0.13. The company had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. The firm's revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.13 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.55 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.68%. Johnson & Johnson's dividend payout ratio is presently 67.06%.
Johnson & Johnson Company Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
- Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.